Marije Van Schalkwyk, Adrie Bekker, Eric Decloedt, Jiajia Wang, Gerhard B Theron, Mark F Cotton, Ahizechukwu C Eke, Tim R Cressey, David E Shapiro, Kira Bacon, Kevin Knowles, Kathleen George, Renee Browning, Nahida Chakhtoura, Kittipong Rungruengthanakit, Lubbe Wiesner, Edmund V Capparelli, Alice M Stek, Mark Mirochnick, Brookie M Best
Physiological changes during pregnancy may alter the pharmacokinetics (PK) of antituberculosis drugs. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1026s was a multicenter, phase IV, observational, prospective PK and safety study of antiretroviral and antituberculosis drugs administered as part of clinical care in pregnant persons living with and without HIV. We assessed the effects of pregnancy on rifampin, isoniazid, ethambutol, and pyrazinamide PK in pregnant and postpartum (PP) persons without HIV treated for drug-susceptible tuberculosis disease...
October 26, 2023: Antimicrobial Agents and Chemotherapy